{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', '9.2.2.', 'Sample Size Sensitivity', 'Figure 3 shows sensitivity of the required sample size to the true response rate for the', 'DTG/3TC FDC arm assuming a 3% failure rate in the current ART non-switch arm and a', '5% margin.', 'Figure 3', 'Sample size sensitivity for the Snapshot Virologic Failure', '600', '1.0', '550', '500', '0.9', '450', '400', '0.8', '350', '300', '0.7', '250', '200', '0.6', '150', '100', '0.5', '50', '0', '0.4', '0.000', '0.005', '0.010', '0.015', '0.020', '0.025', '0.030', '0.035', '0.040', '0.000', '0.005', '0.010', '0.015', '0.020', '0.025', '0.030', '0.035', '0.040', 'Failure Rate for DTG/3TC FDC', 'Failure Rate for DTG/3TC FDC', 'Power=90%, NI margin=5%, control arm failure rate=3%', 'N=245 per arm, NI margin=5%, =', 'control arm failure rate=3%', '9.2.3.', 'Sample Size Re-estimation or Adjustment', 'No further sample size re-estimation will be performed.', '9.3.', 'Populations for Analyses', 'For purposes of analysis, the following populations are defined (the analysis population', 'for genotypic and phenotypic analyses will be fully described in the reporting and', 'analysis plan (RAP]):', 'Population', 'Description', 'Intent-to-Treat Exposed', 'This population will consist of all randomized participants who', 'receive at least one dose of study medication. Participants will be', 'assessed according to their randomized treatment, regardless of the', 'treatment they receive. Unless stated otherwise, the ITT-E', 'Population will be used for efficacy analyses.', '73']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Population', 'Description', 'Per Protocol', 'This population will consist of participants in the ITT-E Population', 'with the exception of protocol deviations which could affect the', 'assessment of antiviral activity. The PP population will be used for', 'sensitivity analyses of the primary efficacy measure. Further details', 'will be described in the RAP.', 'Safety', 'The Safety Population is defined as all randomized participants who', 'take at least 1 dose of study intervention. Participants will be', 'analyzed according to the treatment they actually received. Unless', 'otherwise stated, the Safety Population will be used for safety', 'analyses.', '9.4.', 'Statistical Analyses', 'Additionally, special statistical and data analysis considerations may be warranted in the', 'event that the COVID-19 or related epidemics or natural disasters may affect the study', 'and data integrity. To the extent possible, these will be described in the main study RAP;', 'alternatively, a separate RAP focusing on modified data handling rules (eg, changes to', 'analysis populations, visit windows and endpoints) and analyses (eg, sensitivity analyses', 'to assess impact of and account for missing data) may be prepared, taking in to account', 'applicable regulatory guidance and industry best practices for handling such situations', '[FDA, 2020; EMA, 2020a; EMA, 2020b].', '9.4.1.', 'Efficacy Analyses', 'Enppoint', 'Statistical Analysis Methods', 'Primary', 'For the primary comparison, adjusted estimates of the difference in the', 'virologic failure rate between the two arms will be presented along with Cls', 'based on a stratified analysis using Cochran-Mantel-Haenszel (CMH)', 'weights. All Cls will be two-sided. For the statistical analysis, three strata', '(subgroups) will be formed according to the combinations of levels of the', 'following categorical variables:', 'Baseline third agent: PI', 'Baseline third agent: INI', 'Baseline third agent: NNRTI', 'The CMH estimate of the common difference in rates across strata will be', 'calculated as the weighted average of the strata-specific estimates of the', 'difference in response rates between the two arms as follows:', 'If nk is the number of DTG/3TC FDC treated participants, mk is the number', 'of INI-, NNTRI-, or PI-based ART treated participants, and Nk = nk + mk is', '74']\n\n###\n\n", "completion": "END"}